Sabatel-Pérez, F <br/><br/>
LDL cholesterol-lowering therapies: emphasis on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.  [electronic resource] 

 -  Drugs of today (Barcelona, Spain : 1998)  May 2019 
 - 329-344 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1699-3993 
<br/><br/><label>Standard No.: </label>10.1358/dot.2019.55.5.2976501  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anticholesteremic Agents--therapeutic use<br/>Atherosclerosis--drug therapy<br/>Cardiovascular Diseases--drug therapy<br/>Cholesterol, LDL--antagonists & inhibitors<br/>Humans<br/>PCSK9 Inhibitors<br/>Subtilisins--antagonists & inhibitors